Literature DB >> 15878837

The pivotal role of cytokines in muscle wasting during cancer.

Josep M Argilés1, Sílvia Busquets, Francisco J López-Soriano.   

Abstract

The cachectic syndrome, characterized by a marked weight loss, anorexia, asthenia and anemia, is invariably associated with the presence and growth of the tumour and leads to a malnutrition status due to the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host leads to an accelerated catabolic state, which promotes severe metabolic disturbances in the host, including hypermetabolism, which leads to an increased energetic inefficiency. Although the search for the cachectic factor(s) started a long time ago, and although many scientific and economic efforts have been devoted to its discovery, we are still a long way from knowing the whole truth. Present investigation is devoted to unrevealing the different signaling pathways (particularly transcriptional factors) involved in muscle wasting. The main aim of the present review is to summarize and evaluate the different molecular mechanisms and catabolic mediators involved in cancer cachexia since they may represent targets for future promising clinical investigations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878837     DOI: 10.1016/j.biocel.2005.03.007

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  10 in total

1.  Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1beta.

Authors:  Klemen Strle; Robert H McCusker; Rodney W Johnson; Samantha M Zunich; Robert Dantzer; Keith W Kelley
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-12       Impact factor: 4.310

Review 2.  Osteoporosis in chronic inflammatory disease: the role of malnutrition.

Authors:  Tiziana Montalcini; Stefano Romeo; Yvelise Ferro; Valeria Migliaccio; Carmine Gazzaruso; Arturo Pujia
Journal:  Endocrine       Date:  2012-10-09       Impact factor: 3.633

3.  A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.

Authors:  Danielle N Seto; Susan C Kandarian; Robert W Jackman
Journal:  J Biol Chem       Date:  2015-06-19       Impact factor: 5.157

4.  TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine.

Authors:  Charu Dogra; Harish Changotra; Nia Wedhas; Xuezhong Qin; Jon E Wergedal; Ashok Kumar
Journal:  FASEB J       Date:  2007-02-21       Impact factor: 5.191

5.  The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.

Authors:  Sriram Yennurajalingam; Jie S Willey; J Lynn Palmer; Julio Allo; Egidio Del Fabbro; Evan N Cohen; Sanda Tin; James M Reuben; Eduardo Bruera
Journal:  J Palliat Med       Date:  2012-08-10       Impact factor: 2.947

6.  C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.

Authors:  Evangeline W Cornwell; Azadeh Mirbod; Chia-Ling Wu; Susan C Kandarian; Robert W Jackman
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

7.  The Relationship between Sarcopenia and Systemic Inflammatory Response for Cancer Cachexia in Small Cell Lung Cancer.

Authors:  Eun Young Kim; Young Saing Kim; Ja-Young Seo; Inkeun Park; Hee Kyung Ahn; Yu Mi Jeong; Jeong Ho Kim; Nambeom Kim
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

8.  Cancer cachexia and anabolic interventions: a case report.

Authors:  Edgar L Dillon; Gurjot Basra; Astrid M Horstman; Shanon L Casperson; Kathleen M Randolph; William J Durham; Randall J Urban; Concepcion Diaz-Arrastia; Lyuba Levine; Sandra S Hatch; Maurice Willis; Gwyn Richardson; Melinda Sheffield-Moore
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-15       Impact factor: 12.910

9.  Prognostic value of nutritional markers in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy: a propensity score matching study.

Authors:  Ronald Wihal Oei; Lulu Ye; Juan Huang; Fangfang Kong; Tingting Xu; Chunying Shen; Xiaoshen Wang; Xiayun He; Lin Kong; Chaosu Hu; Hongmei Ying
Journal:  Onco Targets Ther       Date:  2018-08-14       Impact factor: 4.147

10.  Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study.

Authors:  Marta Tenuta; Alain Gelibter; Carla Pandozzi; Grazia Sirgiovanni; Federica Campolo; Mary Anna Venneri; Salvatore Caponnetto; Enrico Cortesi; Paolo Marchetti; Andrea M Isidori; Emilia Sbardella
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.